| __timestamp | Ultragenyx Pharmaceutical Inc. | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 10811000 | 381287000 |
| Thursday, January 1, 2015 | 33001000 | 452612000 |
| Friday, January 1, 2016 | 64936000 | 316800000 |
| Sunday, January 1, 2017 | 99909000 | 330100000 |
| Monday, January 1, 2018 | 127724000 | 265800000 |
| Tuesday, January 1, 2019 | 161524000 | 336200000 |
| Wednesday, January 1, 2020 | 182933000 | 423900000 |
| Friday, January 1, 2021 | 219982000 | 467000000 |
| Saturday, January 1, 2022 | 278139000 | 487000000 |
| Sunday, January 1, 2023 | 309799000 | 477100000 |
Unlocking the unknown
In the competitive landscape of biotechnology, understanding financial trends is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: United Therapeutics Corporation and Ultragenyx Pharmaceutical Inc., from 2014 to 2023.
United Therapeutics has consistently maintained higher SG&A expenses, peaking at approximately $487 million in 2022. This reflects a strategic investment in administrative capabilities and market expansion, with a steady increase of around 28% over the decade.
Ultragenyx, on the other hand, has shown a remarkable growth trajectory in SG&A expenses, surging from $10 million in 2014 to nearly $310 million in 2023. This represents an exponential increase of over 2,800%, highlighting aggressive expansion and scaling efforts.
These trends underscore the differing strategies of these biotech firms in navigating the complex pharmaceutical landscape.
SG&A Efficiency Analysis: Comparing Johnson & Johnson and Ultragenyx Pharmaceutical Inc.
Gilead Sciences, Inc. vs United Therapeutics Corporation: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Ultragenyx Pharmaceutical Inc.
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Genmab A/S
United Therapeutics Corporation and Bio-Techne Corporation: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: United Therapeutics Corporation vs Lantheus Holdings, Inc.
SG&A Efficiency Analysis: Comparing United Therapeutics Corporation and Catalyst Pharmaceuticals, Inc.
Comparing SG&A Expenses: United Therapeutics Corporation vs Bausch Health Companies Inc. Trends and Insights
United Therapeutics Corporation vs Vericel Corporation: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Ultragenyx Pharmaceutical Inc.
Selling, General, and Administrative Costs: Viatris Inc. vs Ultragenyx Pharmaceutical Inc.
Alkermes plc or Ultragenyx Pharmaceutical Inc.: Who Manages SG&A Costs Better?